Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

NCT04221945 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1060

Enrollment

INDUSTRY

Sponsor class

Conditions

Uterine Cervical Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Placebo for pembrolizumab
DRUG: Cisplatin
RADIATION: External Beam Radiotherapy (EBRT)
RADIATION: Brachytherapy

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]
[object Object]